(NASDAQ: CRBU) Caribou Biosciences's forecast annual revenue growth rate of 53.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Caribou Biosciences's revenue in 2026 is $8,806,000.On average, 9 Wall Street analysts forecast CRBU's revenue for 2026 to be $1,090,292,061, with the lowest CRBU revenue forecast at $961,952,397, and the highest CRBU revenue forecast at $1,220,516,156. On average, 8 Wall Street analysts forecast CRBU's revenue for 2027 to be $1,281,809,751, with the lowest CRBU revenue forecast at $1,106,359,314, and the highest CRBU revenue forecast at $1,562,094,056.
In 2028, CRBU is forecast to generate $3,553,342,461 in revenue, with the lowest revenue forecast at $1,117,467,539 and the highest revenue forecast at $10,413,960,375.